广东医学2017，Vol.38Issue(22)：3426-3429,3432,5.
Luminal B型乳腺癌新辅助化疗效果与影响因素分析
Neoadjuvant chemotherapy effect and influencing factors on Luminal B breast cancer
摘要
Abstract
Objective To investigate the effect of neoadjuvant chemotherapy ( NAC) and the influencing factors on pCR of Luminal B breast cancer of different subtypes , and to provide references for clinical intervention and prognosis evaluation .Methods In the retrospective study , the clinical materials of 148 Luminal B breast cancer patients with NAC were collected from November 2010 to July 2016.According to the expression of human epidermal growth factor receptor 2 (HER2), they were divided into HER2 negative and HER2 positive subtypes.They were also divided into pCR and non -pCR groups.The chi-square test and logistic regression were applied for analysis .Results Among the 148 patients, HER2 negative subtype (n=93) and HER2 positive subtype (n=55) significantly differed in treatment regimens, treat-ment cycles and pCR rate ( P<0.05 ); there were 14 patients in pCR group ( 5 of HER2 negative subtype , and 9 of HER2 positive subtype), and 104 in non-pCR group.The pCR was significantly affected by ER status , HER2 status and Ki67 index (P<0.05).Conclusion The response to NAC of Luminal B breast cancer HER 2 positive subtype is better than that of HER2 negative.With the effective treatment, NAC cycles can be prolonged to increase likelihood of pCR . ER negative or low expression, HER2 positive and high expression of Ki67 have some predictive values on the effect of NAC.关键词
Luminal B型乳腺癌/新辅助化疗/疗效/影响因素Key words
Luminal B breast cancer/neoadjuvant chemotherapy/effect/influencing factors引用本文复制引用
仉玮,赖米林,杨时鸿,任黎萍..Luminal B型乳腺癌新辅助化疗效果与影响因素分析[J].广东医学,2017,38(22):3426-3429,3432,5.基金项目
广东省中医药局建设中医药强省科研课题(编号:20151226) （编号:20151226）
